Nubeqa Tablet, Film Coated
Product Images NDC 50419-395

6 FDA label images from Bayer Healthcare Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Nubeqa (NDC 50419-395). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Nubeqa 01)

Chemical Structure (Nubeqa 01)
Chemical structure diagram of darolutamide, the active ingredient in NUBEQA 300 mg film-coated tablets by Bayer HealthCare Pharmaceuticals Inc.*
FDA Label Image

Figure 1 (Nubeqa 02)

Figure 1 (Nubeqa 02)
A Kaplan-Meier survival curve depicting metastasis-free survival probability (%) over time in months from randomization for patients treated with NUBEQA (darolutamide) versus placebo. The graph compares survival between NUBEQA (solid line, N=955) and placebo (dashed line, N=554), with censored data points marked by open circles. A table below the graph shows the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 2 (Nubeqa 03)

Figure 2 (Nubeqa 03)
A survival curve chart showing overall survival probability (%) on the vertical axis and months from randomization on the horizontal axis for patients treated with NUBEQA and placebo. The chart includes two curves: one solid line representing NUBEQA (N=955) and one dashed line representing placebo (N=554), with censored data points marked as circles. Patient numbers at risk for both groups are listed below the chart at various time points up to 60 months.*
FDA Label Image

Figure 3 (Nubeqa 04)

Figure 3 (Nubeqa 04)
A Kaplan-Meier curve chart showing Radiological Progression-free Survival Probability over time in months for two groups: NUBEQA arm and Placebo arm. The chart includes data points with censored events marked and a table below listing the number of patients at risk for each group at different time points up to 39 months.*
FDA Label Image

Figure 4 (Nubeqa 05)

Figure 4 (Nubeqa 05)
A Kaplan-Meier survival curve showing survival probability over time in months for two patient groups: one treated with NUBEQA (darolutamide) combined with docetaxel and a placebo with docetaxel arm. The solid line represents the NUBEQA group, and the dashed line represents the placebo group. The chart includes censored data points marked with circles and a table of the number of patients at risk over time.*
FDA Label Image

Nubeqa 300 mg Label (Nubeqa 06)

Nubeqa 300 mg Label (Nubeqa 06)
NUBEQA 300 mg (darolutamide) film-coated tablets label showing 120 tablets per bottle. The label includes the proprietary and generic names, strength, oral route, Bayer HealthCare Pharmaceuticals Inc. as the labeler, and the NDC 50419-395-01. Additional text includes storage instructions and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.